Tolerability and potential for long term treatment adherence are critical components of any HIV medication regimen 1 . Enfuvirtide (ENF) is an effective antiretroviral (ARV) agent, but requires subcutaneous administration, drug reconstitution, and is associated with potential adverse effects, including injection site reactions 2 . Raltegravir (RAL) is an oral integrase inhibitor with established safety, efficacy, and patient tolerability 3 . As integrase inhibitors are a novel drug class, it is unlikely treatment-experienced patients have significant resistance to RAL 4 .
Patients currently experiencing toxicity and/or adverse drug events on ENF may benefit from changing therapy from ENF to RAL. 
Secondary Objectives
To study the immunologic effect of changing ENF to RAL in HIV-1 infected patients with HIV -1 RNA BLQ on their current HIV regimen.
To assess the quality of life impact of changing ENF to RAL.
To assess safety profile of RAL. Results, cont.
Objectives Inclusion Criteria
HIV-1 infected patients ≥ 18 yrs of age.
Receiving stable ARV regimen consisting of ENF + at least 2 other ARVs for ≥ 6 months.
HIV-1 RNA BLQ for ≥ 6 months prior to study enrollment.
No previous therapy with RAL or any other HIV-1 integrase inhibitor.
Study Design
A multicenter, open-label, historical control study which enrolled patients from 11 Kaiser Permanente HIV clinics in Northern and Southern California, USA.
Patients served as their own control by virtue of at least 6 months of HIV-1 RNA BLQ prior to enrollment into study.
Enrolled subjects changed from ENF to RAL 400mg twice daily, with other ARVs in regimen remaining unchanged.
HIV-1 RNA, CD4 cell count, chemistry, and hematology were performed at Screen/Baseline, Weeks 4, 12, & 24.
Subjects completed a Patient Treatment Satisfaction Survey at Baseline, Weeks 12 and 24.
Treatment failure was defined as HIV-1 >75 copies by bDNA or >50 copies/mL by Ultrasensitive PCR at any study evaluation, with confirmation within 2 weeks of original detectable HIV-1 RNA. 
Results
Among heavily treatment-experienced patients, changing ENF to RAL in a virologically suppressive regimen maintained both virologic and immunologic efficacy at 24 weeks.
RAL therapy was considered to be safe, with minimal adverse effects after treatment change from ENF.
Switching ENF to RAL showed improvement in overall patient treatment satisfaction. 
Conclusions

